About this Journal Submit a Manuscript Table of Contents
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 359683, 9 pages
http://dx.doi.org/10.1155/2013/359683
Review Article

The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection

1Pediatrics and Neonatology Unit, Imola Hospital, Via Montericco 4, 40026 Imola, Italy
2Neonatology, S. Orsola-Malpighi Hospital, Via Massarenti 11, 40138 Bologna, Italy

Received 8 March 2013; Revised 13 May 2013; Accepted 20 May 2013

Academic Editor: Roberto Burioni

Copyright © 2013 Marcello Lanari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Chanock, B. Roizman, and R. Myers, “Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA)—part 1, isolation, properties and characterization,” American Journal of Epidemiology, vol. 66, no. 3, pp. 281–290, 1957. View at Scopus
  2. R. A. Martinello, M. D. Chen, C. Weibel, and J. S. Kahn, “Correlation between respiratory syncytial virus genotype and severity of illness,” Journal of Infectious Diseases, vol. 186, no. 6, pp. 839–842, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Gilca, G. De Serres, M. Tremblay et al., “Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons,” Journal of Infectious Diseases, vol. 193, no. 1, pp. 54–58, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. E. A. F. Simoes, “Respiratory syncytial virus infection,” Lancet, vol. 354, no. 9181, pp. 847–852, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. T. G. Boyce, B. G. Mellen, E. F. Mitchel Jr., P. F. Wright, and M. R. Griffin, “Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid,” Journal of Pediatrics, vol. 137, no. 6, pp. 865–870, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Leader, K. Kohlhase, M. H. Pearlman, J. V. Williams, and W. A. Engle, “Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000,” Journal of Pediatrics, vol. 143, no. 5, supplement, pp. S127–S132, 2003. View at Scopus
  7. L. C. Paramore, V. Ciuryla, G. Ciesla, and L. Liu, “Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases,” PharmacoEconomics, vol. 22, no. 5, pp. 275–284, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. W. W. Thompson, D. K. Shay, E. Weintraub et al., “Mortality associated with influenza and respiratory syncytial virus in the United States,” Journal of the American Medical Association, vol. 289, no. 2, pp. 179–186, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Nair, V. R. Verma, E. Theodoratou et al., “An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children,” BMC Public Health, vol. 11, no. 3, supplement, article S30, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. C. B. Hall, G. A. Weinberg, M. K. Iwane et al., “The Burden of respiratory syncytial virus infection in young children,” New England Journal of Medicine, vol. 360, no. 6, pp. 588–598, 2009. View at Scopus
  11. D. K. Shay, R. C. Holman, R. D. Newman, L. L. Liu, J. W. Stout, and L. J. Anderson, “Bronchiolitis-associated hospitalizations among US children, 1980-1996,” Journal of the American Medical Association, vol. 282, no. 15, pp. 1440–1446, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. R. C. Welliver, D. F. Willison, and C. A. Scott, “Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection,” Journal of Pediatrics, vol. 143, no. 5, supplement, pp. S112–S117, 2003. View at Scopus
  13. B. Resch, P. Manzoni, and M. Lanari, “Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes,” Paediatric Respiratory Reviews, vol. 10, no. 3, pp. 148–153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. E. A. F. Simoes, “Immunoprophylaxis of respiratory syncytial virus infection,” Indian Pediatrics, vol. 37, no. 3, pp. 243–247, 2000. View at Scopus
  15. E. E. L. Wang, B. J. Law, and D. Stephens, “Pediatric investigators collaborative network on infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection,” Journal of Pediatrics, vol. 126, no. 2, pp. 212–219, 1995. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Figueras-Aloy, X. Carbonell-Estrany, and J. Quero, “Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33–35 weeks in Spain,” Pediatric Infectious Disease Journal, vol. 23, no. 9, pp. 815–820, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Lanari, M. Giovannini, L. Giuffré et al., “Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity,” Pediatric Pulmonology, vol. 33, no. 6, supplement, pp. 458–465, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Lanari, F. Adorni, M. Silvestri, A. Coscia, and M. Musicco, “The multicenter Italian birth cohort study on incidence and determinants of lower respiratory tract infection hospitalization in infants at 33weeks GA or more: preliminary results,” Early Human Development, vol. 87, supplement, pp. S43–S46, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. J. G. Liese, E. Grill, B. Fischer et al., “Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany,” European Journal of Pediatrics, vol. 162, no. 4, pp. 230–236, 2003. View at Scopus
  20. J. S. Sampalis and J. V. Williams, “Morbidity and mortality after RSV-associated hospitalizations among premature canadian infants,” Journal of Pediatrics, vol. 143, no. 5, supplement, pp. S150–S156, 2003. View at Scopus
  21. E. A. F. Simoes, “Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease,” Journal of Pediatrics, vol. 143, no. 5, supplement, pp. S118–S126, 2003. View at Scopus
  22. J. A. I. Weigl, W. Puppe, and H.-J. Schmitt, “Can respiratory syncytial virus etiology be diagnosed clinically? A hospital-based case-control study in children under two years of age,” European Journal of Epidemiology, vol. 18, no. 5, pp. 431–439, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Baraldi and M. Filippone, “Chronic lung disease after premature birth,” New England Journal of Medicine, vol. 357, no. 19, pp. 1946–1955, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Lanari, G. A. Rossi, R. Merolla, U. Di Luzio Paparatti, and T. F. Feltes, “High risk of nosocomial-acquired RSV infection in children with congenital heart disease,” Journal of Pediatrics, vol. 145, no. 1, pp. 140–141, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Zachariah, M. Ruttenber, and E. A. F. Simões, “Down syndrome and hospitalizations due to respiratory syncytial virus: a population-based study,” Journal of Pediatrics, vol. 160, no. 5, pp. 827–831, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Luján-Zilbermann, E. Benaim, X. Tong, D. K. Srivastava, C. C. Patrick, and J. P. DeVincenzo, “Respiratory virus infections in pediatric hematopoietic stem cell transplantation,” Clinical Infectious Diseases, vol. 33, no. 7, pp. 962–968, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. H. B. Panitch, “Bronchiolitis in infants,” Current Opinion in Pediatrics, vol. 13, no. 3, pp. 256–260, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Wilkesmann, R. A. Ammann, O. Schildgen et al., “Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course,” Pediatric Infectious Disease Journal, vol. 26, no. 6, pp. 485–491, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. J. R. Groothuis, J. M. Hoopes, and V. G. Hemming, “Prevention of serious respiratory syncytial virus-related illness—II: immunoprophylaxis,” Advances in Therapy, vol. 28, no. 2, pp. 110–125, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Lanari, M. Silvestri, and G. A. Rossi, “Clinical and pharmacological aspects of immunoprophylaxis for respiratory syncytial virus infection in high-risk infants,” Current Drug Metabolism, vol. 14, no. 2, pp. 216–225, 2013.
  31. B. Geevarghese and E. A. Simões, “Antibodies for prevention and treatment of respiratory syncytial virus infections in children,” Antiviral Therapy, vol. 17, no. 1, pp. 201–211, 2012.
  32. L. J. Gershwin, “Immunology of bovine respiratory syncytial virus infection of cattle,” Comparative Immunology, Microbiology & Infectious Diseases, vol. 35, no. 3, pp. 253–257, 2012.
  33. G. A. Prince, V. G. Hemming, R. L. Horswood, and R. M. Chanock, “Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat,” Virus Research, vol. 3, no. 3, pp. 193–206, 1985. View at Scopus
  34. J. R. Groothuis, M. J. Levin, W. Rodriguez et al., “Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics,” Antimicrobial Agents and Chemotherapy, vol. 35, no. 7, pp. 1469–1473, 1991. View at Scopus
  35. H. C. Meissner, D. R. Fulton, J. R. Groothuis et al., “Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin,” Antimicrobial Agents and Chemotherapy, vol. 37, no. 8, pp. 1655–1658, 1993. View at Scopus
  36. J. R. Groothuis, E. A. F. Simoes, M. J. Levin et al., “Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children,” New England Journal of Medicine, vol. 329, no. 21, pp. 1524–1530, 1993. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Connor, “Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis,” Pediatrics, vol. 99, no. 1, pp. 93–99, 1997. View at Publisher · View at Google Scholar · View at Scopus
  38. J. R. Groothuis and H. Nishida, “Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab),” Pediatrics International, vol. 44, no. 3, pp. 235–241, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. E. A. F. Simoes, H. M. Sondheimer, J. Top F.H. et al., “Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease infants and children with congenital heart disease,” Journal of Pediatrics, vol. 133, no. 4, pp. 492–499, 1998. View at Publisher · View at Google Scholar · View at Scopus
  40. J. R. Groothuis and E. A. F. Simoes, “Immunoprophylaxis and immunotherapy: role in the prevention and treatment of respiratory syncytial virus,” International Journal of Antimicrobial Agents, vol. 2, no. 2, pp. 97–104, 1993. View at Publisher · View at Google Scholar · View at Scopus
  41. Oravax, Oravax Company Press Release, 1997.
  42. B. García-Barreno, C. Palomo, C. Peñas, T. Delgado, P. Perez-Breña, and J. A. Melero, “Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins,” Journal of Virology, vol. 63, no. 2, pp. 925–932, 1989. View at Scopus
  43. H. C. Meissner, J. R. Groothuis, W. J. Rodriguez et al., “Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 5, pp. 1183–1188, 1999. View at Scopus
  44. J. A. Beeler and K. Van Wyke Coelingh, “Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function,” Journal of Virology, vol. 63, no. 7, pp. 2941–2950, 1989. View at Scopus
  45. J. Arbiza, G. Taylor, J. A. Lopez et al., “Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus,” Journal of General Virology, vol. 73, no. 9, pp. 2225–2234, 1992. View at Scopus
  46. K. Huang, L. Incognito, X. Cheng, N. D. Ulbrandt, and H. Wu, “Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion,” Journal of Virology, vol. 84, no. 16, pp. 8132–8140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Johnson, C. Oliver, G. A. Prince et al., “Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus,” Journal of Infectious Diseases, vol. 176, no. 5, pp. 1215–1224, 1997. View at Scopus
  48. A. Z. Kapikian, R. H. Mitchell, R. M. Chanock, R. A. Shvedoff, and C. E. Stewart, “An epidemiologic study of altered clinical reactivity to Respiratory Syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine,” American Journal of Epidemiology, vol. 89, no. 4, pp. 405–421, 1969. View at Scopus
  49. J. P. DeVincenzo, C. B. Hall, D. W. Kimberlin et al., “Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-Resistant mutants,” Journal of Infectious Diseases, vol. 190, no. 5, pp. 975–978, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. Q. Zhu, J. M. McAuliffe, N. K. Patel et al., “Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab,” Journal of Infectious Diseases, vol. 203, no. 5, pp. 674–682, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. E. M. Connor, “Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants,” Pediatrics, vol. 102, no. 3 I, pp. 531–537, 1998. View at Publisher · View at Google Scholar · View at Scopus
  52. S.-Y. Wu, J. Bonaparte, and S. Pyati, “Palivizumab use in very premature infants in the neonatal intensive care unit,” Pediatrics, vol. 114, no. 5, pp. e554–e556, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. R. Malley, J. Devincenzo, O. Ramilo et al., “Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein,” Journal of Infectious Diseases, vol. 178, no. 6, pp. 1555–1561, 1998. View at Publisher · View at Google Scholar · View at Scopus
  54. G. R. Siber, D. Leombruno, J. Leszczynski et al., “Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin,” Journal of Infectious Diseases, vol. 169, no. 6, pp. 1368–1373, 1994. View at Scopus
  55. D. Null Jr., B. Pollara, P. H. Dennehy et al., “Safety and immunogenicity of palivizumab (Synagis) administered for two seasons,” Pediatric Infectious Disease Journal, vol. 24, no. 11, pp. 1021–1023, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. T. F. Feltes, A. K. Cabalka, H. C. Meissner et al., “Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease,” Journal of Pediatrics, vol. 143, no. 4, pp. 532–540, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. Abbott Laboratories, Data on file. Abbott Laboratories; International Division, Abbott Park; Ill, USA, 2000.
  58. X. Sáez-Llorens, E. Castaño, D. Null et al., “Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia,” Pediatric Infectious Disease Journal, vol. 17, no. 9, pp. 787–791, 1998. View at Publisher · View at Google Scholar · View at Scopus
  59. Committee on Infectious Disease. American Academy of Pediatrics, “Policy statement—modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections,” Pediatrics, vol. 124, no. 6, pp. 1694–1701, 2009.
  60. B. Resch and I. Michel-Behnke, “Respiratory syncytial virus infections in infants and children with congenital heart disease: update on the evidence of prevention with palivizumab,” Current Opinion in Cardiology, vol. 28, no. 2, pp. 85–91, 2013.
  61. E. A. F. Simões, X. Carbonell-Estrany, C. H. L. Rieger, I. Mitchell, L. Fredrick, and J. R. Groothuis, “The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children,” Journal of Allergy and Clinical Immunology, vol. 126, no. 2, pp. 256–262, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. G. Faldella, R. Alessandroni, G. Aquilano et al., “Hospitalization for lower respiratory tract disease in preterm infants: effects of prophylaxis with palivizumab,” Journal of Chemotherapy, vol. 22, no. 1, pp. 30–35, 2010. View at Scopus
  63. X. Sáez-Llorens, M. T. Moreno, O. Ramilo, P. J. Sánchez, F. H. Top Jr., and E. M. Connor, “Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratoy syncytial virus infection,” Pediatric Infectious Disease Journal, vol. 23, no. 8, pp. 707–712, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Mejías, S. Chávez-Bueno, A. M. Ríos et al., “Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus Potency,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 11, pp. 4700–4707, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Wu, D. S. Pfarr, Y. Tang et al., “Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization,” Journal of Molecular Biology, vol. 350, no. 1, pp. 126–144, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. H. Wu, D. S. Pfarr, S. Johnson et al., “Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract,” Journal of Molecular Biology, vol. 368, no. 3, pp. 652–665, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. P. Fernández, A. Trenholme, K. Abarca et al., “A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season,” BMC Pediatrics, vol. 10, article 38, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. E. A. Simoes, X. Carbonell-Estrany, G. Losonsky, M. Hultquist, B. Harris, and E. Connor, “Phase III trial of motavizumab; an enhanced potency respiratory syncytial virus (RSV)-specific monoclonal antibody for the prevention of serious RSV disease in high risk infants,” Acta Paediatrica, vol. 96, no. s456, pp. 232–233, 2007.
  69. K. Abarca, E. Jung, P. Fernández et al., “Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children,” Pediatric Infectious Disease Journal, vol. 28, no. 4, pp. 267–272, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Lanari, M. Silvestri, and G. A. Rossi, “Palivizumab prophylaxis in 'late preterm' newborns,” Journal of Maternal-Fetal and Neonatal Medicine, vol. 23, no. 3, supplement, pp. 53–55, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. X. Carbonell-Estrany, L. Bont, G. Doering, J.-B. Gouyon, and M. Lanari, “Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 27, no. 10, pp. 891–899, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Lanari, M. Silvestri, and G. A. Rossi, “Respiratory syncytial virus risk factors in late preterm infants,” Journal of Maternal-Fetal and Neonatal Medicine, vol. 22, no. 3, pp. 102–107, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. L. B. Weiner, A. S. Masaquel, M. J. Polak, and P. J. Mahadevia, “Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States,” Journal of Medical Economics, vol. 15, no. 5, pp. 997–1018, 2012.
  74. B. Resch, C. Sommer, M. J. C. Nuijten et al., “Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria,” Pediatric Infectious Disease Journal, vol. 31, no. 1, pp. e1–e8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. M. J. Nuijten and W. Wittenberg, “Cost effectiveness of palivizumab in Spain: an analysis using observational data,” European Journal of Health Economics, vol. 11, no. 1, pp. 105–115, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. P. Manzoni, B. Paes, B. Resch, X. Carbonell-Estrany, and L. Bont, “High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention,” Early Human Development, vol. 88, no. 2, supplement, pp. S34–S41, 2012.